Colchicine + Rosuvastatin for Heart Disease

(PRE-EMPT Trial)

This trial aims to determine if early treatment can benefit individuals with mild heart disease by reducing or stabilizing plaque (cholesterol build-up) in heart arteries. Special scans will screen participants for plaque, and they may receive medications like rosuvastatin (a cholesterol-lowering drug) and colchicine (an anti-inflammatory) or a placebo. Ideal candidates are those without current heart disease symptoms but with risk factors, such as a history of cholesterol build-up. Participants will receive heart-healthy lifestyle advice and have regular check-ins over two years. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.

Yes, you will need to stop taking any current lipid-lowering therapy or colchicine, as the trial excludes participants who are currently or have previously used these medications.

Previous studies have shown that rosuvastatin is safe and effective in lowering cholesterol and reducing the risk of heart problems, such as heart attacks and strokes. Many patients benefit from rosuvastatin without major issues, though some may experience muscle pain or weakness.

Colchicine, often used to reduce inflammation, has also been found to lower the risk of heart-related problems. It is generally well-tolerated, but some individuals might experience stomach issues, such as diarrhea.

Researchers are excited about the combination of colchicine and rosuvastatin for heart disease because it brings a fresh approach to treatment. Unlike typical therapies which mainly focus on lowering cholesterol, this combination targets inflammation, a key player in heart disease. Colchicine is known for its anti-inflammatory properties, while rosuvastatin is a powerful statin that lowers cholesterol. Together, they might address both inflammation and cholesterol levels, potentially offering a more comprehensive treatment. This dual-action approach could lead to better outcomes for patients compared to standard treatments that only target cholesterol.

Research has shown that rosuvastatin, a cholesterol-lowering drug, can reduce the risk of heart attacks and strokes. Studies indicate it can lower heart-related risks by about 24% in individuals with moderate risk. Similarly, colchicine, which reduces inflammation, has decreased major heart issues by about 31% in patients with stable heart conditions. In this trial, participants will join different treatment arms: some will receive rosuvastatin with a colchicine-matched placebo, others will receive colchicine with a rosuvastatin-matched placebo, and some will receive both rosuvastatin and colchicine. These drugs work together to combat heart disease by targeting cholesterol and inflammation, key factors in arterial plaque buildup. While some evidence suggests benefits from using these treatments together, researchers continue to study their full effect on heart health.¹³⁴⁵⁶